grant
Atrioventricular Block Elimination by Rozanolixizumab Treatment
Organization NEW YORK UNIVERSITY SCHOOL OF MEDICINELocation NEW YORK, UNITED STATESPosted 15 Sept 2025Deadline 30 Jun 2030
NIHUS FederalResearch GrantFY20250-11 years old0-4 weeks old21+ years old2nd trimester3rd trimester7S Gamma GlobulinAccelerationAddressAdultAdult HumanAdverse ExperienceAdverse eventAffectAntibodiesApproaches to preventionAtrioventricular BlockAutoantibodiesAutoantibody bindingAutoantibody reactivityBenchmarkingBest Practice AnalysisBindingBiological AgentBiological ProductsBlocking AntibodiesCanadaCardiacCardiac DiseasesCardiac DisordersCardiomyopathiesCell Communication and SignalingCell SignalingCells Placenta-TissueChildChild YouthChildren (0-21)CirculationClinical Treatment MoabCord BloodDataDevelopmentDiseaseDisorderDrug KineticsDrugsDysfunctionEarly DiagnosisEchocardiogramEchocardiographyEndocardial FibroelastosisEnrollmentExhibitsExposure toFDA approvedFaceFatality rateFetal Heart RateFetusFibrosis in the heartFibrosis in the myocardiumFibrosis within the heartFibrosis within the myocardiumFibrotic myocardiumFunctional disorderGestationGoalsHeartHeart DiseasesHigh-Risk PregnancyHourHydroxychlorochinHydroxychloroquineIGIVIV ImmunoglobulinsIVIGIgGIgG ReceptorsImmune globulin IVImmunoglobulin GImmunoglobulin G ReceptorImmunologistIndividuals from minorityIndividuals of minorityInfusionInfusion proceduresIntracellular Communication and SignalingIntravenous AntibodiesIntravenous IGIntravenous Immune GlobulinIntravenous ImmunoglobulinsLast TrimesterMacrophageMaternal-Fetal ExchangeMaternal-fetal medicineMeasurementMeasuresMediatingMedicationMidtrimesterMinority GroupsMinority PeopleMinority PopulationMinority individualMolecular InteractionMonitorMonoclonal AntibodiesMorbidityMorbidity - disease rateMothersMyasthenia GravisMyocardial DiseasesMyocardial DisorderMyocardial depressionMyocardial dysfunctionMyocardiopathiesMφNICHDNational Institute of Child Health and Human DevelopmentNeonatalNeonatal lupusNeonatal lupus erythematosusNewborn InfantNewbornsNormal PlacentomaOxychlorochinOxychloroquinePathogenesisPathogenicityPatientsPharmaceutical PreparationsPharmacodynamicsPharmacokineticsPhysiopathologyPlacentaPlacenta Embryonic TissuePlacentomePregnancyPregnancy ComplicationsPregnant WomenPreventative strategyPreventionPrevention approachPrevention strategyPreventive strategyReceptor SignalingRecurrenceRecurrentRecyclingReportingResearchRibonucleoproteinsRiskRo antibodiesSS-A antibodiesSafetySecond Pregnancy TrimesterSecond TrimesterSiblingsSignal TransductionSignal Transduction SystemsSignalingSurvivorsSymptomsSyncytiotrophoblastTLR proteinTestingTherapeuticThird Pregnancy TrimesterThird TrimesterTimeToll-Like Receptor Family GeneToll-like receptorsTranslatingTransplacental ExposureTransthoracic EchocardiographyTreatment EfficacyUmbilical CordUmbilical Cord BloodUmbilical cord structureWomanWorkadulthoodarmautoimmune antibodyautoreactive antibodybenchmarkbiological signal transductionbiologicsbiopharmaceuticalbiotherapeutic agentcardiac dysfunctioncardiac fibrosiscardiac rhythmcomplications during pregnancycoronary fibrosisdesigndesigningdetermine efficacydevelopmentaldrug/agentearly adulthoodearly detectionearly in pregnancyearly pregnanciesearly pregnancyearly stage of pregnancyefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationemerging adultenrollevaluate efficacyexamine efficacyexpectant motherexpectant womenexpecting motherexpecting womenfacesfacialfetalfetal cord bloodfibrotic heartgamma Fc Receptorsheart disorderheart dysfunctionheart fibrosisheart rhythmheart sonographyimprovedin vitro Modelindividuals who are pregnantinfusionsintervention efficacykidsmAbsmaternal safetymaternal-fetal interfacemonoclonal Absmyocardial fibrosismyocardium diseasemyocardium disordernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynewborn childnewborn childrennext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyoffspringopen labelopen label studypathophysiologypediatric cardiologistpeople who are pregnantplacental transferpregnancy-related complicationspregnantpregnant femalespregnant motherspregnant peoplepregnant populationspreventpreventingprospectiverecruitrecurrence preventionrheumatologistself reactive antibodysubcutaneoussubdermaltherapeutic efficacytherapy efficacythose who are pregnantwomen who are pregnantyoungster
Description preview
Abstract
Selectively targeting IgG recycling at the maternal-fetal interface to reduce pathogenic IgG by inhibition of the
fetal neonatal Fc gamma receptor (FcRn) and acceleration of IgG destruction, carries the potential to eradicate
autoantibody mediated diseases affirming the prediction “no antibody, no disease.” The nearly invariant finding
of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click